Clinical Report: Investigating the Clinical Relevance and Functional Role of RRN3 in Gastric Cancer

Overview

This study evaluates the role of RRN3 in gastric cancer, highlighting its upregulation in multiple tumor types and association with poor survival outcomes.

Background

Gastric cancer (GC) is a leading cause of cancer-related mortality, particularly in developing countries, due to late-stage diagnosis and limited therapeutic options. Identifying molecular factors associated with GC progression is crucial for improving early diagnosis and treatment strategies. RRN3, a nucleolar protein involved in ribosome biogenesis, has been linked to cancer progression, making it a relevant target for study.

Data Highlights

RRN3 was found to be upregulated in gastric cancer tissues and associated with various clinicopathological features related to tumor progression. High RRN3 expression correlated with unfavorable overall survival in multiple cancers.

Key Findings

• RRN3 expression is upregulated in gastric cancer and other tumor types.
• High RRN3 levels are associated with unfavorable overall survival across several cancers.
• In gastric cancer, RRN3 correlates with RNA methylation regulators and immune checkpoint genes.
• Knockdown of RRN3 inhibits gastric cancer cell proliferation, migration, and invasion.
• In vivo experiments confirm RRN3's role in promoting tumor growth.

Clinical Implications

Further investigation into RRN3's role could provide insights into new therapeutic strategies targeting ribosome biogenesis in cancer.

Conclusion

RRN3 is implicated in gastric cancer progression and may represent a candidate for future research aimed at understanding its role in cancer biology.

Related Resources & Content

1. Journal of Gastroenterology, 2015 -- Analysis of Long Non-Coding RNA Expression Patterns Linked to Varying Metastatic Capabilities in Gastric Cancer
2. Gastric Cancer, 2023 -- Identification of LncRNA Expression Patterns Through Genome-Wide Transcriptomic Analysis for Predicting Lymph Node Metastasis in Stage T1 and T2 Gastric Cancer Patients
3. Gastric Cancer, 2021 -- Molecular Changes, Treatment Strategies by Stage, and Future Challenges in Signet Ring Cell Carcinoma of the Stomach and Gastroesophageal Junction
4. PubMed, 2025 -- Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
5. PubMed, 2025 -- Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
6. PubMed, 2023 -- The impact of ribosome biogenesis in cancer: from proliferation to metastasis
7. Expression of Gastrin-Releasing Peptide and Its Receptor in Tumor-Associated Macrophages of Clear Cell Renal Cell Carcinoma: Implications for Immune Cell Modulation
8. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 - PubMed
9. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study - PubMed
10. The impact of ribosome biogenesis in cancer: from proliferation to metastasis - PubMed